Skip to main content Skip to footer

Orexo press releases

Update on the FDA review for Abstral™

7 September 2010 at 08:15 – Regulatory

Update on the FDA review for Abstral™

Orexo notes significant change in its owner structure

26 August 2010 at 17:30 – Regulatory

Orexo notes significant change in its owner structure

Orexo AB (publ.) – Interim report, January-June 2010

20 August 2010 at 08:01 – RegulatoryReportQ2

Orexo AB (publ.) – Interim report, January-June 2010

Orexo confirms Abstral PDUFA date update

2 June 2010 at 13:30 – Regulatory

Orexo confirms Abstral PDUFA date update

Orexo reports continued strong AbstralTM sales in Europe

18 May 2010 at 08:15 – Regulatory

Orexo reports continued strong AbstralTM sales in Europe

Orexo AB (publ) – Interim report, January-March 2010

5 May 2010 at 08:00 – RegulatoryReportQ1

Orexo AB (publ) – Interim report, January-March 2010

Report from Orexo AB’s Annual General Meeting, April 21, 2010

21 April 2010 at 19:45 – RegulatoryGeneral Meeting

Report from Orexo AB’s Annual General Meeting, April 21, 2010

Novo transaction completed

7 April 2010 at 11:15 – Regulatory

Novo transaction completed

Report from the extraordinary general meeting in Orexo AB (publ), 31 March 2010

31 March 2010 at 13:00 – RegulatoryGeneral Meeting

Report from the extraordinary general meeting in Orexo AB (publ), 31 March 2010

Notice of Annual General Meeting in Orexo AB

23 March 2010 at 23:00 – RegulatoryGeneral Meeting

Notice of Annual General Meeting in Orexo AB

Notice of Extraordinary General Meeting

15 March 2010 at 08:00 – RegulatoryGeneral Meeting

Notice of Extraordinary General Meeting

Orexo AB (publ.) – Year-end Report January-December 2009

17 February 2010 at 08:00 – RegulatoryReportQ4

Orexo AB (publ.) – Year-end Report January-December 2009

Orexo confirms Canadian Regulatory Filing of Abstral

4 February 2010 at 12:00 – Regulatory

Orexo confirms Canadian Regulatory Filing of Abstral

IR & Corporate Communications Director

Lena Wange

Subscribe